CoChat
Sign Up
PreprintCited by 1

Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer’s disease

Wang, Lihua, Nykänen, Niko-Petteri, Western, Daniel, Gorijala, Priyanka, Timsina, Jigyasha, Li, Fuhai, Wang, Zhaohua, Ali, Muhammad +23 more·2023
DOI 10.1101/2023.06.14.23291409

Preprint — published as 10.1186/s13024-023-00687-4 · Paper page

Open this paper in CoChat — free account

Abstract

Triggering receptor expressed on myeloid cells 2 (TREM2) plays a critical role in microglial activation, survival, and apoptosis, as well as in Alzheimer’s disease (AD) pathogenesis. We previously reported the MS4A locus as a key modulator for soluble TREM2 (sTREM2) in cerebrospinal fluid (CSF). To identify additional novel genetic modifiers of sTREM2, we performed the largest genome-wide association study (GWAS) and identified four loci for CSF sTREM2 in 3350 individuals of European ancestry. Through multi-ethnic fine mapping, we identified two independent missense variants (p.M178V in MS4A4A and p.A112T in MS4A6A ) that drive the association in MS4A locus and showed an epistatic effect for sTREM2 levels and AD risk. The novel TREM2 locus on chr 6 contains two rare missense variants (rs75932628 p.R47H, P=7.16×10 -19 ; rs142232675 p.D87N, P=2.71×10 -10 ) associated with sTREM2 and AD risk. The third novel locus in the TGFBR2 and RBMS3 gene region (rs73823326, P=3.86×10 -9 ) included a regulatory variant with a microglia-specific chromatin loop for the promoter of TGFBR2 . Using cell-based assays we functionally validated that overexpression of TGFBR2 increased sTREM2 and silencing reduced sTREM2, whereas modulating RBMS3 did not. The last novel locus NECTIN2 on chr 19 (rs11666329, P=2.52×10 -8 ) was independent of APOE genotype and colocalized with cis-eQTL of NECTIN2 in the brain cortex and cis-pQTL of NECTIN2 in CSF. To our knowledge, this is the largest study to date aimed at identifying genetic modifiers of CSF sTREM2. This study provided novel insights into the MS4A and TREM2 loci, two well-known AD risk genes, and identified TGFBR2 and NECTIN2 as additional modulators involved in TREM2 biology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2023.06.14.23291409

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 84

  1. Di Battista AM, Heinsinger NM, Rebeck GW. Alzheimer's disease genetic risk factor APOE-epsilon4 also affects normal brain function. Curr Alzhei- mer Res. 2016;13:1200-7.
  2. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, et al. Variant of TREM2 associ- ated with the risk of Alzheimer's disease. N Engl J Med. 2013;368:107-16.
  3. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cru- chaga C, Sassi C, Kauwe JS, Younkin S, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368:117-27.
  4. Benitez BA, Cooper B, Pastor P, Jin SC, Lorenzo E, Cervantes S, Cruchaga C. TREM2 is associated with the risk of Alzheimer's disease in Spanish population. Neurobiol Aging. 2013;34(1711):e1715-1717.
  5. Jin SC, Benitez BA, Karch CM, Cooper B, Skorupa T, Carrell D, Norton JB, Hsu S, Harari O, Cai Y, et al. Coding variants in TREM2 increase risk for Alzheimer's disease. Hum Mol Genet. 2014;23:5838-46.
  6. Jin SC, Carrasquillo MM, Benitez BA, Skorupa T, Carrell D, Patel D, Lincoln S, Krishnan S, Kachadoorian M, Reitz C, et al. TREM2 is associated with increased risk for Alzheimer's disease in African Americans. Mol Neurode- gener. 2015;10:19.
  7. Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet. 2019;51:414-30.
  8. Bellenguez C, Kucukali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, Naj AC, Campos-Martin R, Grenier-Boley B, Andrade V, et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet. 2022;54:412-36.
  9. Yang J, Fu Z, Zhang X, Xiong M, Meng L, Zhang Z. TREM2 ectodomain and its soluble form in Alzheimer's disease. J Neuroinflammation. 2020;17:204.
  10. Kim SM, Mun BR, Lee SJ, Joh Y, Lee HY, Ji KY, Choi HR, Lee EH, Kim EM, Jang JH, et al. TREM2 promotes Abeta phagocytosis by upregulating C/EBPal- pha-dependent CD36 expression in microglia. Sci Rep. 2017;7:11118.
  11. Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, et al. Complement and micro- glia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712-6.
  12. Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, Giustetto M, Ferreira TA, Guiducci E, Dumas L, et al. Synaptic prun- ing by microglia is necessary for normal brain development. Science. 2011;333:1456-8.
  13. Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA, Stevens B. Microglia sculpt postnatal neural circuits in an activity and complement-dependent man- ner. Neuron. 2012;74:691-705.
  14. Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell. 2015;160:1061-71.
  15. Lee CYD, Daggett A, Gu X, Jiang LL, Langfelder P, Li X, Wang N, Zhao Y, Park CS, Cooper Y, et al. Elevated TREM2 gene dosage reprograms micro- glia responsivity and ameliorates pathological phenotypes in Alzheimer's disease models. Neuron. 2018;97(1032-1048): e1035.
  16. Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Remolina Serrano J, Robinson GO, Anderson E, Colonna M, Holtzman DM. TREM2 defi- ciency attenuates neuroinflammation and protects against neurode- generation in a mouse model of tauopathy. Proc Natl Acad Sci U S A. 2017;114:11524-9.
  17. Jay TR, von Saucken VE, Landreth GE. TREM2 in Neurodegenerative diseases. Mol Neurodegener. 2017;12:56.
  18. Kiianitsa K, Kurtz I, Beeman N, Matsushita M, Chien WM, Raskind WH, Korvatska O. Novel TREM2 splicing isoform that lacks the V-set immu- noglobulin domain is abundant in the human brain. J Leukoc Biol. 2021;110:829-37.
  19. Filipello F, Goldsbury C, You SF, Locca A, Karch CM, Piccio L. Soluble TREM2: innocent bystander or active player in neurological diseases? Neurobiol Dis. 2022;165: 105630.
  20. Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger-Weinzierl A, Mazaheri F, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6:243ra286.
  21. Piccio L, Deming Y, Del-Aguila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, Borroni B, Cruchaga C. Cerebrospinal fluid solu- ble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 2016;131:925-33.
  22. Suarez-Calvet M, Kleinberger G, Araque Caballero MA, Brendel M, Rominger A, Alcolea D, Fortea J, Lleo A, Blesa R, Gispert JD, et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med. 2016;8:466-76.
  23. Suarez-Calvet M, Araque Caballero MA, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Ewers M, Haass C. Dominantly Inherited Alzheimer N: Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. Sci Transl Med. 2016;8:369ra178.
  24. Park SH, Lee EH, Kim HJ, Jo S, Lee S, Seo SW, Park HH, Koh SH, Lee JH. The relationship of soluble TREM2 to other biomarkers of sporadic Alzhei- mer's disease. Sci Rep. 2021;11:13050.
  25. Ewers M, Biechele G, Suarez-Calvet M, Sacher C, Blume T, Morenas- Rodriguez E, Deming Y, Piccio L, Cruchaga C, Kleinberger G, et al. Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation. EMBO Mol Med. 2020;12: e12308.
  26. Hou XH, Bi YL, Tan MS, Xu W, Li JQ, Shen XN, Dou KX, Tan CC, Tan L. Alz- heimer's Disease Neuroimaging I, Yu JT: Genome-wide association study identifies Alzheimer's risk variant in MS4A6A influencing cerebrospinal fluid sTREM2 levels. Neurobiol Aging. 2019;84:241 e213-241 e220.
  27. Gu S, Pakstis AJ, Li H, Speed WC, Kidd JR, Kidd KK. Significant variation in haplotype block structure but conservation in tagSNP patterns among global populations. Eur J Hum Genet. 2007;15:302-12.
  28. Schwartzentruber J, Cooper S, Liu JZ, Barrio-Hernandez I, Bello E, Kuma- saka N, Young AMH, Franklin RJM, Johnson T, Estrada K, et al. Genome- wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer's disease risk genes. Nat Genet. 2021;53:392-402.
  29. Jansen IE, van der Lee SJ, Gomez-Fonseca D, de Rojas I, Dalmasso MC, Grenier-Boley B, Zettergren A, Mishra A, Ali M, Andrade V, et al. Genome- wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomark- ers. Acta Neuropathol. 2022;144:821-42.
  30. Huang KL, Marcora E, Pimenova AA, Di Narzo AF, Kapoor M, Jin SC, Harari O, Bertelsen S, Fairfax BP, Czajkowski J, et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease. Nat Neurosci. 2017;20:1052-61.
  31. Del-Aguila JL, Fernandez MV, Schindler S, Ibanez L, Deming Y, Ma S, Saef B, Black K, Budde J, Norton J, et al. Assessment of the genetic architecture of Alzheimer's disease risk in rate of memory decline. J Alzheimers Dis. 2018;62:745-56.
  32. Nott A, Holtman IR, Coufal NG, Schlachetzki JCM, Yu M, Hu R, Han CZ, Pena M, Xiao J, Wu Y, et al. Brain cell type-specific enhancer-promoter interactome maps and disease-risk association. Science. 2019;366:1134-9.
  33. Vosa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, Kirsten H, Saha A, Kreuzhuber R, Yazar S, et al. Large-scale cis-and trans-eQTL analy- ses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet. 2021;53:1300-10.
  34. Consortium GT. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science. 2020;369:1318-30.
  35. de Klein N, Tsai EA, Vochteloo M, Baird D, Huang Y, Chen CY, van Dam S, Oelen R, Deelen P, Bakker OB, et al. Brain expression quantitative trait locus and network analyses reveal downstream effects and putative driv- ers for brain-related diseases. Nat Genet. 2023;55:377.
  36. Lopes KP, Snijders GJL, Humphrey J, Allan A, Sneeboer MAM, Navarro E, Schilder BM, Vialle RA, Parks M, Missall R, et al. Genetic analysis of the human microglial transcriptome across brain regions, aging and disease pathologies. Nat Genet. 2022;54:4-17.
  37. Morenas-Rodriguez E, Li Y, Nuscher B, Franzmeier N, Xiong C, Suarez- Calvet M, Fagan AM, Schultz S, Gordon BA, Benzinger TLS, et al. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. Lancet Neurol. 2022;21:329-41.
  38. Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, Ohrfelt A, Blennow K, Hardy J, Schott J, et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. Mol Neurodegener. 2016;11:3.
  39. Suarez-Calvet M, Morenas-Rodriguez E, Kleinberger G, Schlepckow K, Araque Caballero MA, Franzmeier N, Capell A, Fellerer K, Nuscher B, Eren E, et al. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-beta pathol- ogy. Mol Neurodegener. 2019;14:1.
  40. Phillips B, Western D, Wang L, Timsina J, Sun Y, Gorijala P, Yang C, Do A, Nykänen N-P, Alvarez I, et al. Proteome wide association studies of LRRK2 variants identify novel causal and druggable for Parkinson's disease. medRxiv. 2023;9:107.
  41. Akiyama M, Ishigaki K, Sakaue S, Momozawa Y, Horikoshi M, Hirata M, Matsuda K, Ikegawa S, Takahashi A, Kanai M, et al. Characterizing rare and low-frequency height-associated variants in the Japanese population. Nat Commun. 2019;10:4393.
  42. Barton AR, Sherman MA, Mukamel RE, Loh PR. Whole-exome imputation within UK Biobank powers rare coding variant association and fine- mapping analyses. Nat Genet. 2021;53:1260-9.
  43. Kichaev G, Bhatia G, Loh PR, Gazal S, Burch K, Freund MK, Schoech A, Pasaniuc B, Price AL. Leveraging polygenic functional enrichment to improve GWAS Power. Am J Hum Genet. 2019;104:65-75.
  44. Vuckovic D, Bao EL, Akbari P, Lareau CA, Mousas A, Jiang T, Chen MH, Raf- field LM, Tardaguila M, Huffman JE, et al. The polygenic and monogenic basis of blood traits and diseases. Cell. 2020;182(1214-1231): e1211.
  45. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018;50:928-36.
  46. Chen MH, Raffield LM, Mousas A, Sakaue S, Huffman JE, Moscati A, Trivedi B, Jiang T, Akbari P, Vuckovic D, et al. Trans-ethnic and ancestry-specific blood-cell genetics in 746,667 individuals from 5 global populations. Cell. 2020;182(1198-1213): e1114.
  47. Park JS, Ji IJ, Kim DH, An HJ, Yoon SY. The Alzheimer's disease-associated R47H variant of TREM2 has an altered glycosylation pattern and protein stability. Front Neurosci. 2016;10:618.
  48. Tesseur I, Zou K, Esposito L, Bard F, Berber E, Can JV, Lin AH, Crews L, Tremblay P, Mathews P, et al. Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. J Clin Invest. 2006;116:3060-9.
  49. Zoller T, Schneider A, Kleimeyer C, Masuda T, Potru PS, Pfeifer D, Blank T, Prinz M, Spittau B. Silencing of TGFbeta signalling in microglia results in impaired homeostasis. Nat Commun. 2018;9:4011.
  50. Shimizu K, Takai Y. Roles of the intercellular adhesion molecule nectin in intracellular signaling. J Biochem. 2003;134:631-6.
  51. Mizutani K, Miyata M, Shiotani H, Kameyama T, Takai Y. Nectin-2 in general and in the brain. Mol Cell Biochem. 2022;477:167-80.
  52. Lunemann A, Lunemann JD, Roberts S, Messmer B, BarreiradaSilva R, Raine CS, Munz C. Human NK cells kill resting but not activated microglia via NKG2D-and NKp46-mediated recognition. J Immunol. 2008;181:6170-7.
  53. Miyata M, Mandai K, Maruo T, Sato J, Shiotani H, Kaito A, Itoh Y, Wang S, Fujiwara T, Mizoguchi A, et al. Localization of nectin-2delta at perivas- cular astrocytic endfoot processes and degeneration of astrocytes and neurons in nectin-2 knockout mouse brain. Brain Res. 2016;1649:90-101.
  54. Guardiola M, Muntane G, Martinez I, Martorell L, Girona J, Ibarretxe D, Plana N, Bullido MJ, Vilella E, Ribalta J. Metabolic overlap between Alzhei- mer's disease and metabolic syndrome identifies the PVRL2 gene as a new modulator of diabetic Dyslipidemia. Int J Mol Sci. 2023;24:7415.
  55. Logue MW, Schu M, Vardarajan BN, Buros J, Green RC, Go RC, Griffith P, Obisesan TO, Shatz R, Borenstein A, et al. A comprehensive genetic association study of Alzheimer disease in African Americans. Arch Neurol. 2011;68:1569-79.
  56. Bailey CC, DeVaux LB, Farzan M. The triggering receptor expressed on myeloid cells 2 binds Apolipoprotein E. J Biol Chem. 2015;290:26033-42.
  57. Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, Li X, Rademakers R, Kang SS, Xu H, et al. Apolipoprotein E is a Ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J Biol Chem. 2015;290:26043-50.
  58. Edwin TH, Henjum K, Nilsson LNG, Watne LO, Persson K, Eldholm RS, Saltvedt I, Halaas NB, Selbaek G, Engedal K, et al. A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer's disease. Alzheimers Dement (Amst). 2020;12: e12128.
  59. Moreno-Grau S, de Rojas I, Hernandez I, Quintela I, Montrreal L, Alegret M, Hernandez-Olasagarre B, Madrid L, Gonzalez-Perez A, Maronas O, et al. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. Alzheimers Dement. 2019;15:1333-47.
  60. Alvarez I, Diez-Fairen M, Aguilar M, Gonzalez JM, Ysamat M, Tartari JP, Carcel M, Alonso A, Brix B, Arendt P, Pastor P. Added value of cerebrospinal fluid multimarker analysis in diagnosis and progression of dementia. Eur J Neurol. 2021;28:1142-52.
  61. Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Simuni T, Jennings D, Tanner CM, Trojanowski JQ, et al. The Parkinson's At BMC, research is always in progress. Learn more biomedcentral.com/submissions Ready to submit your research Ready to submit your research ? Choose BMC and benefit from: ? Choose BMC and benefit from: progression markers initiative (PPMI) -establishing a PD biomarker cohort. Ann Clin Transl Neurol. 2018;5:1460-77.
  62. Winfree RL, Dumitrescu L, Blennow K, Zetterberg H, Gifford KA, Pechman KR, Jefferson AL, Hohman TJ. Alzheimer's disease neuroimaging I: biologi- cal correlates of elevated soluble TREM2 in cerebrospinal fluid. Neurobiol Aging. 2022;118:88-98.
  63. Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN, Carter J, Dalby AB, Eaton BE, Fitzwater T, et al. Aptamer-based multiplexed proteomic tech- nology for biomarker discovery. PLos One. 2010;5: e15004.
  64. Candia J, Cheung F, Kotliarov Y, Fantoni G, Sellers B, Griesman T, Huang J, Stuccio S, Zingone A, Ryan BM, et al. Assessment of variability in the SOMAscan assay. Sci Rep. 2017;7:14248.
  65. Timsina J, Gomez-Fonseca D, Wang L, Do A, Western D, Alvarez I, Aguilar M, Pastor P, Henson RL, Herries E, et al. Comparative analysis of Alzhei- mer's Disease cerebrospinal fluid biomarkers measurement by multiplex SOMAscan platform and immunoassay-based approach. J Alzheimers Dis. 2022;89:193-207.
  66. Feng W, Beer JC, Hao Q, Ariyapala IS, Sahajan A, Komarov A, Cha K, Moua M, Qiu X, Xu X, Iyengar S, Yoshimura T, Nagaraj R, Wang L, Yu M, Engel K, Zhen L, Xue W, Lee CJ, Park CH, Peng C, Zhang K, Grzybowski A, Hahm J, Schmidt SV, Odainic A, Spitzer J, Buddika K, Kuo D, Fang L, Zhang B, Chen S, Latz E, Yin Y, Luo Y, Ma XJ. NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing. Nat Commun. 2023;14(1):7238. https:// doi. org/ 10. 1038/ s41467-023-42834-x. · DOI
  67. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second- generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7.
  68. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26:2190-1.
  69. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, Boehnke M, Abecasis GR, Willer CJ. LocusZoom: regional visualization of genome- wide association scan results. Bioinformatics. 2010;26:2336-7.
  70. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-5.
  71. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet. 2011;88:76-82.
  72. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, Flicek P, Cunningham F. The ensembl variant effect predictor. Genome Biol. 2016;17:122.
  73. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, Langdon R, et al. The MR-Base platform sup- ports systematic causal inference across the human phenome. Elife. 2018;7:e34408.
  74. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wal- lace C, Plagnol V. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10: e1004383.
  75. Choi SW, O'Reilly PF. PRSice-2: polygenic risk score software for biobank- scale data. Gigascience. 2019;8:giz082.
  76. Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrmisdottir EL, Gunnarsdottir K, Helgason A, Oddsson A, Halldorsson BV, et al. Large-scale integration of the plasma proteome with genetics and disease. Nat Genet. 2021;53:1712-21.
  77. Timsina J, Ali M, Do A, Wang L, Sung YJ, Cruchaga C. Harmonization of CSF and imaging biomarkers for Alzheimer's disease biomarkers: need and practical applications for genetics studies and preclinical classifica- tion. bioRxiv. 2023:2023.05.24.542118. https:// doi. org/ 10. 1101/ 2023. 05. 24. 542118. · DOI
  78. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403-13.
  79. Blennow K, Shaw LM, Stomrud E, Mattsson N, Toledo JB, Buck K, Wahl S, Eichenlaub U, Lifke V, Simon M, et al. Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Abeta(1-42), pTau and tTau CSF immunoassays. Sci Rep. 2019;9:19024.
  80. Kaplow J, Vandijck M, Gray J, Kanekiyo M, Huyck E, Traynham CJ, Esquivel R, Fagan AM, Luthman J. Concordance of Lumipulse cerebrospinal fluid t-tau/Abeta42 ratio with amyloid PET status. Alzheimers Dement. 2020;16:144-52.
  81. Alegret M, Sotolongo-Grau O, de Antonio EE, Perez-Cordon A, Orellana A, Espinosa A, Gil S, Jimenez D, Ortega G, Sanabria A, et al. Automatized FACEmemory(R) scoring is related to Alzheimer's disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort. Alzheimers Res Ther. 2022;14:43.
  82. Belsare KD, Wu H, Mondal D, Bond A, Castillo E, Jin J, Jo H, Roush AE, Pilla KB, Sali A, et al. Soluble TREM2 inhibits secondary nucleation of Abeta fibrillization and enhances cellular uptake of fibrillar Abeta. Proc Natl Acad Sci U S A. 2022;119:e2114486119.
  83. Akhter R, Shao Y, Formica S, Khrestian M, Bekris LM. TREM2 alters the phagocytic, apoptotic and inflammatory response to Abeta(42) in HMC3 cells. Mol Immunol. 2021;131:171-9.
  84. Moutinho M, Coronel I, Tsai AP, Di Prisco GV, Pennington T, Atwood BK, Puntambekar SS, Smith DC, Martinez P, Han S, et al. TREM2 splice isoforms generate soluble TREM2 species that disrupt long-term potentiation. Genome Med. 2023;15:11.

Cited by

Sorted by citations

Authors
Wang, L., Nykänen, N.-P., Western, D., Gorijala, P., Timsina, J., Li, F., Wang, Z., Ali, M., Yang, C., Marquié, M., Boada, M., Alvarez, I., Aguilar, M., Pastor, P., Ruiz, A., Puerta, R., Orellana, A., Rutledge, J., Oh, H., Greicius, M. D., Guen, Y. L., Perrin, R. J., Wyss-Coray, T., Jefferson, A., Hohman, T. J., Graff-Radford, N., Mori, H., Goate, A., Levin, J., Sung, Y. J., & Cruchaga, C.
ORCID
Publisher
openRxiv
Published
2023-06-20
DOI
10.1101/2023.06.14.23291409
Cited by
1
References
0
Type
Preprint

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review